$CVS, that proposed to buy $AET, reported a 17% drop in its 3Q17 profit, mainly due to reimbursement pressure and $187MM of losses on pension settlements. Net income during the quarter fell to $1.28Bil, or $1.26 per share, from $1.54Bil, or $1.44 per share during 3Q16. Adj. EPS was $1.50, down...
Celgene earnings details. A cut in the outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma company's R&D expenses is not a good sign.
I had this very interesting conversation today with a liberal feminist. She said, that since female sexual protection and birth control pills are available, there should be an off the shelf ready availability of male sex reduction pills too. The interesting part was, that she assumed, that...